dihexa cancer risk AngIV-Analog Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway DIHEXA is changing the conversation
Description
Phase 1/2 trial reported no serious adverse events at doses up to 60 mcg/kg (Teichman et al., J Clin Endocrinol Metab 2006)
- Quantity: 30 capsules
Smith, P
These analogs have been shown to facilitate the formation of new functional synaptic connections, induce long-term potentiation (LTP), and augment memory consolidation and retrieval in animal models of AD
[DOI] [PMC free article] [PubMed] [Google Scholar] 52.Mas-Orea X., Basso L., Blanpied C., Gaveriaux-Ruff C., Cenac N., Dietrich G
Endocrinology 1993;133:286170.ArticlePubMed 21
